Astrana Health, Inc. reiterated earnings guidance for the year ending December 31, 2024. For the year, the company expects total revenue in the range of $1,650.0 million to $1,850.0 million, Net income attributable to Astrana Health, Inc. in the range of $61.0 million to $73.0 million and EPS ? diluted in the range of $1.28 to $1.52.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.55 USD | -2.87% |
|
+4.30% | +5.87% |
May. 30 | Baird Starts Astrana Health With Outperform Rating, $54 Price Target | MT |
May. 16 | Transcript : Astrana Health, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 10:00 AM |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.87% | 2.04B | |
+25.01% | 89.22B | |
-22.75% | 76.59B | |
+3.24% | 26.87B | |
-8.76% | 17.41B | |
+1.00% | 17.25B | |
+0.23% | 15.25B | |
+78.95% | 13.43B | |
+71.14% | 13.26B | |
-24.74% | 13.22B |
- Stock Market
- Equities
- ASTH Stock
- News Astrana Health, Inc.
- Astrana Health, Inc. Reiterates Earnings Guidance for the Year Ending December 31, 2024